Alberto Farolfi, MD, PhD, discusses bevacizumab plus SOC in advanced cervical cancer and no contraindications for antiangiogenic agents.
Alberto Farolfi, MD, PhD
Advertisement
Alberto Farolfi, MD, PhD, is a medical oncologist at Romagnolo Scientific Institute for the Study and Treatment of Tumors
Articles by Alberto Farolfi, MD, PhD
Alberto Farolfi, MD, PhD, discusses real-world findings with bevacizumab plus platinum-based chemotherapy and pembrolizumab in advanced cervical cancer.
Advertisement
Latest Updated Articles
Dr Farolfi on a Real-World Study of Bevacizumab Plus SOC Therapy in Cervical CancerPublished: September 19th 2025 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
3
Aligning Patient Goals and Toxicity Burden Are Key in First-Line Chemo Selection in Pancreatic Cancer
4
Novel Targeted Agents Are Poised to Influence the MPN Treatment Paradigm: With John O. Mascarenhas, MD
5